Advances in Biopharmaceutical Technology in India

India has one of the largest populations and fastest growing economies in the world. The country’s biopharmaceutical industry has grown dramatically over the past few years, with sales exceeding US$1.5 billion. As domestic demand for improved healthcare, and international opportunities for biologics increase, India will continue to expand its presence on the world biopharmaceutical stage.

This study describes the Indian biopharmaceutical industry, its history, advantages and opportunities, as well as its challenges and risks. Biopharmaceutical products have a long history in India, and trace their roots back several thousand years through schools of healing practice. The Indian government is actively developing that experience into a sound biotech industry. We cover Indian government policies that enable the manufacture of modern biotech products at affordable prices, and discuss the technologies and patent factors that have shaped the Indian industry.

The next decade should show a significant growth in the Indian biotech industry, and this study discusses how novel biotech drugs may ultimately dominate. India is expected to emerge as a strong player as its biotech industry develops a globally competitive local industry that stands on a foundation of basic research. This volume provides an in-depth view of the biopharmaceutical industry in India. It describes the current state of technology, partnership opportunities, and general business practices. Readers are provided thorough, peer-reviewed analysis of business opportunities to help them identify potential partners and create an effective India Strategy.

The study is a ready reference for biopharmaceuticals in India, including technical and business issues, and detailed information on companies, universities, and government organizations involved in biopharmaceuticals.

By the Numbers:
-35 Internationally Recognized Authors
-766 Pages
-20 Chapters
-14 Peer reviewers
-1,178 References
-118 Tables and 49 Figures

What You’ll Get:

-Expert, unbiased, analysis: 35 internationally recognized authors, sponsored by Society for Industrial Microbiology

-Peer-reviewed: Editorial board and review ensures content was reviewed by a blue-ribbon board of industry experts for accuracy, relevance, and substance.

-Unparalleled access to experts: Purchasers have unique access to study contributors and authors.

-Content based on explicit needs of the industry: Extensive pre-development survey was used to determine study content.

-Fresh, relevant information: Subject matter experts combine their in-depth knowledge with current, primary data. SHOW LESS READ MORE >

PART 1: Introduction
Chapter 1 Prospects for Modern Biotechnology in India

PART 2: State of India's Life Sciences Industry
Chapter 2 A Window into India's Biopharma Sector
Chapter 3 Indian Biopharmaceutical System and Policies
Chapter 4 Government Support for Biotech and Biopharmaceuticals Industry
Chapter 5 Biopharmaceutical Products in India.
Chapter 6 Biogeneric Manufacturing in India
Chapter 7 Biopharmaceutical Market Situation.
Chapter 8 The Contract Research Industry in India
Chapter 9 Regulatory Landscape for Clinical Trials in India
INDIA BRIEF 1 Pre-Clinical and Clinical Trial in India
Chapter 10 Life Sciences Education in India

PART 3: Scientific Issues in India
Chapter 11 Vaccine Industry in India
Chapter 12 Development of Plasma-Derived Biopharmaceuticals in India: Challenges and Opportunities
Chapter 13 Bioprocess Expression and Production Technologies in India
INDIA BRIEF 2 Technology Transfer: Impact and Importance for Indian Biotechnology Growth
Chapter 14 Application of Recent Advances in Immunology for Developing Novel Biotherapeutics in India
Chapter 15 Early-stage Key R&D Components for Successful Development of Protein Therapeutics
Chapter 16 Understanding Ayurveda Medicine

PART 4: Biobusiness in India
Chapter 17 Biopharmaceutical Outsourcing: A Overview--India and China
Chapter 18 Biopharmaceutical Research Collaborations between India and the West: Prospective Partnerships
Chapter 19 Outsourcing R&D to India
INDIA BRIEF 3 Outsourcing Biopharma R&D to India
Chapter 20 Venture Capital in India Today
Organizations Represented (Authors)
Amgen, Inc.
Apothecaries Ltd.
beòcarta Ltd.
Bharat Biotech International Ltd.
BioPlan Associates, Inc.
Biospectrum Asia
Cadila Pharmaceuticals Ltd.
CanBiotech
Celestial Biologicals Ltd
Chiltern International Private Ltd.
Dow AgroSciences LLC
Endocrine Technology, LLC
Finston Consulting, LLC
GAEA Resources Inc.
Health Interactions
J. Sagar Associates
John Curling Consulting AB
M J Biopharm Pvt. Ltd.
Magnetical
National Institute of Health
National Institute of Science Technology and Development Studies
Neo BioMed Services
ProMetic BioTherapeutics, Inc.
Serum Institute of India Ltd.
Strategic Manufacturing Worldwide, Inc.
Uniformed Services University of the Health Sciences.
Reviewers from:
Bharat Biotech, India
Biotech Consultant LLC, USA
Cadila Pharmaceuticals Ltd., India
Excel Life Sciences, Inc., USA
Falconridge Associates, Inc.
Institute of Bioinformatics and Applied Biotechnology (IBAB), India
John Curling Consulting, Sweden
Madhav Institute of Technology and Science, India
National Institute of Science Technology and Development Studies, India
Newport Biotech
Strategic Manufacturing Worldwide, Inc.
University of Illinois, USA
University of Iowa, USA

Amgen, Inc.
Apothecaries Ltd.
beòcarta Ltd.
Bharat Biotech International Ltd.
BioPlan Associates, Inc.
Biospectrum Asia
Cadila Pharmaceuticals Ltd.
CanBiotech
Celestial Biologicals Ltd
Chiltern International Private Ltd.
Dow AgroSciences LLC
Endocrine Technology, LLC
Finston Consulting, LLC
GAEA Resources Inc.
Health Interactions
J. Sagar Associates
John Curling Consulting AB
M J Biopharm Pvt. Ltd.
Magnetical
National Institute of Health
National Institute of Science Technology and Development Studies
Neo BioMed Services
ProMetic BioTherapeutics, Inc.
Serum Institute of India Ltd.
Strategic Manufacturing Worldwide, Inc.
Uniformed Services University of the Health Sciences.